Anti-VEGF Treatment Strategies for Wet AMD

Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.

[1]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[2]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[3]  U. Schmidt-Erfurth,et al.  Effect of intravitreal bevacizumab (Avastin®) in neovascular age‐related macular degeneration using a treatment regimen based on optical coherence tomography: 6‐ and 12‐month results , 2009, Acta ophthalmologica.

[4]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[5]  P. Rosenfeld,et al.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. , 2005, Ophthalmology.

[6]  E. Gragoudas,et al.  Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. , 2000, Archives of ophthalmology.

[7]  E. Lenassi,et al.  Efficacy of 12‐month treatment of neovascular age‐related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections , 2011, Acta ophthalmologica.

[8]  J. Nowak,et al.  Age-related macular degeneration (AMD): pathogenesis and therapy. , 2006, Pharmacological reports : PR.

[9]  T. Ianchulev,et al.  A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. , 2009, Ophthalmology.

[10]  K. Freund,et al.  “TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION , 2009, Retina.

[11]  A. Saad,et al.  Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. , 2009, American journal of ophthalmology.

[12]  U. Schmidt-Erfurth,et al.  Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. , 2011, Ophthalmology.

[13]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[14]  P. Rosenfeld.  Bevacizumab!versus!Ranibizumab!—!The!Verdict , 2011 .

[15]  S. Bressler.  Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. , 2009, Ophthalmology.

[16]  A. Schakal,et al.  Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. , 2008, American journal of ophthalmology.

[17]  R. Avery,et al.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[18]  P. Rosenfeld.  Bevacizumab versus ranibizumab for AMD. , 2011, The New England journal of medicine.

[19]  M. Maia,et al.  Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. , 2010, Ophthalmology.

[20]  Philip J Rosenfeld,et al.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[21]  Cathy Frey,et al.  Investigative Ophthalmology and Visual Science , 2010 .

[22]  Q. Mohamed,et al.  Intravitreal bevacizumab (Avastin) for neovascular age‐related macular degeneration using a variable frequency regimen in eyes with no previous treatment , 2008, Clinical & experimental ophthalmology.

[23]  M. Stewart.  PREDICTED BIOLOGIC ACTIVITY OF INTRAVITREAL BEVACIZUMAB , 2007, Retina.

[24]  U. Schmidt-Erfurth,et al.  Primary Results of an International Phase III Study Using Intravitreal VEGF Trap-Eye Compared to Ranibizumab in Patients with Wet AMD (VIEW 2) , 2011 .

[25]  A. Ho,et al.  Randomized, Double-masked, Active-controlled Phase 3 Trial Of The Efficacy And Safety Of Intravitreal VEGF Trap-Eye In Wet AMD: One-year Results Of The View-1 Study , 2011 .

[26]  L. Damico,et al.  DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[27]  D. Fei,et al.  Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. , 2005, Investigative ophthalmology & visual science.

[28]  M. Brantley,et al.  Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab , 2008, British Journal of Ophthalmology.

[29]  Ivana K. Kim,et al.  Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. , 2005, Archives of ophthalmology.

[30]  C. Regillo,et al.  A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. , 2010, Ophthalmology.

[31]  P. Rosenfeld,et al.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. , 2006, Ophthalmology.

[32]  Philip J Rosenfeld,et al.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.

[33]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. , 2007, Ophthalmology.

[34]  Manju Patel,et al.  Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[35]  P. Mitchell,et al.  Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials , 2009, British Journal of Ophthalmology.

[36]  J. Pulido,et al.  Pharmacokinetics of intravitreal ranibizumab (Lucentis). , 2007, Ophthalmology.

[37]  R. Steinbrook,et al.  The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. , 2006, The New England journal of medicine.

[38]  L. da Cruz,et al.  Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study , 2010, BMJ : British Medical Journal.

[39]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[40]  C. Regillo,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.

[41]  P. Abraham,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. , 2010, American journal of ophthalmology.

[42]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[43]  Joan W. Miller,et al.  Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. , 2002, Archives of ophthalmology.

[44]  R. Casson,et al.  Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age‐related macular degeneration in an Australian population , 2010, Clinical & experimental ophthalmology.

[45]  R. Tadayoni,et al.  INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED: A Comparative Retrospective Study of Ranibizumab in Exudative Age-Related Macular Degeneration , 2011, Retina.